297 related articles for article (PubMed ID: 20110049)
1. Cost-effectiveness of pentostatin compared with cladribine in the management of hairy cell leukemia in the United Kingdom.
Guest JF; Smith H; Sladkevicius E; Jackson G
Clin Ther; 2009; 31 Pt 2():2398-415. PubMed ID: 20110049
[TBL] [Abstract][Full Text] [Related]
2. Long remissions in hairy cell leukemia with purine analogs: a report of 219 patients with a median follow-up of 12.5 years.
Else M; Ruchlemer R; Osuji N; Del Giudice I; Matutes E; Woodman A; Wotherspoon A; Swansbury J; Dearden C; Catovsky D
Cancer; 2005 Dec; 104(11):2442-8. PubMed ID: 16245328
[TBL] [Abstract][Full Text] [Related]
3. Long-term results for pentostatin and cladribine treatment of hairy cell leukemia.
Dearden CE; Else M; Catovsky D
Leuk Lymphoma; 2011 Jun; 52 Suppl 2():21-4. PubMed ID: 21599603
[TBL] [Abstract][Full Text] [Related]
4. Rituximab with pentostatin or cladribine: an effective combination treatment for hairy cell leukemia after disease recurrence.
Else M; Dearden CE; Matutes E; Forconi F; Lauria F; Ahmad H; Kelly S; Liyanage A; Ratnayake V; Shankari J; Whalley I; Catovsky D
Leuk Lymphoma; 2011 Jun; 52 Suppl 2():75-8. PubMed ID: 21504288
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Outcomes of Hairy Cell Leukemia Treated With Purine Analogs: A Comparison With the General Population.
Madanat YF; Rybicki L; Radivoyevitch T; Jagadeesh D; Dean R; Pohlman B; Kalaycio M; Sekeres MA; Smith MR; Hill BT
Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):857-862. PubMed ID: 28778620
[TBL] [Abstract][Full Text] [Related]
6. [Hairy cell leukemia--a potentially curable malignancy. Selected aspects of purine analog therapy].
Rucińska M; Machaczka M; Załuska A; Skotnicki AB
Przegl Lek; 1998; 55(7-8):400-6. PubMed ID: 10021885
[TBL] [Abstract][Full Text] [Related]
7. Extended follow-up of patients with hairy cell leukemia after treatment with cladribine.
Goodman GR; Burian C; Koziol JA; Saven A
J Clin Oncol; 2003 Mar; 21(5):891-6. PubMed ID: 12610190
[TBL] [Abstract][Full Text] [Related]
8. Long-term follow-up of patients with hairy cell leukaemia after treatment with pentostatin or cladribine.
Dearden CE; Matutes E; Hilditch BL; Swansbury GJ; Catovsky D
Br J Haematol; 1999 Aug; 106(2):515-9. PubMed ID: 10460614
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England.
Hettle R; Harty G; Wong SL
J Med Econ; 2018 Jul; 21(7):676-686. PubMed ID: 29618273
[TBL] [Abstract][Full Text] [Related]
10. Long-term follow-up after purine analogue therapy in hairy cell leukaemia.
Else M; Dearden CE; Catovsky D
Best Pract Res Clin Haematol; 2015 Dec; 28(4):217-29. PubMed ID: 26614900
[TBL] [Abstract][Full Text] [Related]
11. My treatment approach to hairy cell leukemia.
Naik RR; Saven A
Mayo Clin Proc; 2012 Jan; 87(1):67-76. PubMed ID: 22212971
[TBL] [Abstract][Full Text] [Related]
12. Hairy-cell leukaemia: first-line treatment with cladribine or pentostatin.
Prescrire Int; 2006 Aug; 15(84):143-4. PubMed ID: 16989031
[TBL] [Abstract][Full Text] [Related]
13. Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis.
Else M; Dearden CE; Matutes E; Garcia-Talavera J; Rohatiner AZ; Johnson SA; O'Connor NT; Haynes A; Osuji N; Forconi F; Lauria F; Catovsky D
Br J Haematol; 2009 Jun; 145(6):733-40. PubMed ID: 19344416
[TBL] [Abstract][Full Text] [Related]
14. Cladribine in the treatment of hairy cell leukemia: initial and subsequent results.
Huynh E; Sigal D; Saven A
Leuk Lymphoma; 2009 Oct; 50 Suppl 1():12-7. PubMed ID: 19814692
[TBL] [Abstract][Full Text] [Related]
15. Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine).
Füreder W; Weltermann A; Chott A; Gisslinger H; Valent P; Jäger U; Geissler K; Lechner K
Wien Klin Wochenschr; 1999 Dec; 111(24):1027-30. PubMed ID: 10677889
[TBL] [Abstract][Full Text] [Related]
16. The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent/refractory hairy cell leukemia.
Else M; Osuji N; Forconi F; Dearden C; Del Giudice I; Matutes E; Wotherspoon A; Lauria F; Catovsky D
Cancer; 2007 Nov; 110(10):2240-7. PubMed ID: 17886250
[TBL] [Abstract][Full Text] [Related]
17. Long-term follow-up of patients with hairy cell leukemia after cladribine treatment.
Saven A; Burian C; Koziol JA; Piro LD
Blood; 1998 Sep; 92(6):1918-26. PubMed ID: 9731048
[TBL] [Abstract][Full Text] [Related]
18. Hairy cell leukemia treated initially with purine analogs: a retrospective study of 107 patients from the Spanish Cooperative Group on Chronic Lymphocytic Leukemia (GELLC).
López Rubio M; Da Silva C; Loscertales J; Seri C; Baltasar P; Colado E; Pérez Fernández I; Osma M; Gomis F; González M; Jarque I; Vargas M; Monzó E; Monteagudo D; Orts MI; Pardal E; Carbonell F; Perez Calvo C; Garcia-Marco JA
Leuk Lymphoma; 2014 May; 55(5):1007-12. PubMed ID: 23885799
[TBL] [Abstract][Full Text] [Related]
19. Pentostatin: impact on outcome in hairy cell leukemia.
Grever MR
Hematol Oncol Clin North Am; 2006 Oct; 20(5):1099-108. PubMed ID: 16990110
[TBL] [Abstract][Full Text] [Related]
20. Long-term outcome following treatment of hairy cell leukemia with pentostatin (Nipent): a National Cancer Institute of Canada study.
Johnston JB; Eisenhauer E; Wainman N; Corbett WE; Zaentz SD; Daeninck PJ
Semin Oncol; 2000 Apr; 27(2 Suppl 5):32-6. PubMed ID: 10877049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]